STOCK TITAN

Sutro Biopharma to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Sutro Biopharma, Inc. (STRO) CEO Bill Newell to participate in three upcoming investor conferences to present at Oppenheimer 34th Annual Healthcare Life Sciences Conference, TD Cowen 44th Annual Health Care Conference, and Barclays 26th Annual Global Healthcare Conference. Webcasts of the presentations will be accessible through the company’s website.
Positive
  • None.
Negative
  • None.

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences.

Conference Details:

Oppenheimer 34th Annual Healthcare Life Sciences Conference
Date: February 13-14, 2024
Location: Virtual

TD Cowen 44th Annual Health Care Conference
Date: March 3-6, 2024
Location: Boston

Barclays 26th Annual Global Healthcare Conference
Date: March 12-14, 2024
Location: Miami

Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. Archived replays will be available for at least 30 days after the event.

About Sutro Biopharma

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com. 

Contact
Emily White 
Sutro Biopharma 
(650) 823-7681
ewhite@sutrobio.com


FAQ

When will CEO Bill Newell participate in the upcoming investor conferences?

CEO Bill Newell will participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14, 2024, TD Cowen 44th Annual Health Care Conference on March 3-6, 2024, and Barclays 26th Annual Global Healthcare Conference on March 12-14, 2024.

Where will the investor conferences take place?

The Oppenheimer conference will be virtual, the TD Cowen conference will be in Boston, and the Barclays conference will be in Miami.

How can I access the webcasts of the presentations?

The webcasts will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com.

How long will the replays of the presentations be available?

Archived replays will be available for at least 30 days after the events.

Sutro Biopharma, Inc.

NASDAQ:STRO

STRO Rankings

STRO Latest News

STRO Stock Data

302.45M
81.96M
0.96%
78.2%
3.49%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOUTH SAN FRANCISCO